Press Release

August 16, 2022
Fuji Pharma Co., Ltd.

Submitted for approval of 1st co-developed product with Lotus

Fuji Pharma Co., Ltd. ("Fuji") announced that Fuji has submitted for approval of a generic drug co-developed in Japan with Lotus Pharmaceutical Co., Ltd. (Head Office: Taiwan, TPEX ticker:1795, "Lotus") to the Ministry of Health, Labor and Welfare (MHLW).

Fuji and Lotus have entered into a capitalization and business alliance agreement with the aim of introducing Lotus' pipeline in Japan, as described in "Lotus and Fuji Confirm Cross‐Investment Partnership to Further Strengthen Their Positions in Asia" on March 20, 2019. And, the product is the first co-development project achieved by Lotus and Fuji and is a product, as described in "Fuji Pharma and Lotus finalized co-development and license agreement for the 1st high value generic product in Japan" on August 13, 2021. The submission will further strengthen Fuji's domestic product line-up.

Based on our corporate philosophy of "We help people lead healthy lives by offering excellent pharmaceuticals," Fuji will provide new treatment options to patients and medical professionals through the supply of this product. Fuji will continue our efforts to expand our product lineup and make further contributions in the healthcare field and the healthcare economy.

[About Lotus]
Founded in 1966, Lotus (1795: TT) now is the largest pharmaceutical company in Taiwan with high-value generic products covering CNS, CVS, women health, and anti-obesity drugs in tablets and hard/softgel capsule with a special focus on oral oncology for global markets.
By leveraging a best-in-class R&D and manufacturing platform in Asia, Lotus aims to benefit patients, its employees and stakeholders. Furthermore, Lotus can reach nearly every global market with its high value pipeline through its direct markets, currently encompassing Taiwan, Korea, Thailand, Vietnam, Singapore, Hong Kong, Malaysia, Philippines, and China, or via alliances with top-tier pharma companies based on its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

For further information, contact
Fuji Pharma Co., Ltd.
Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division
fsk_ir@fujipharma.jp